Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib (X-82) in Wet AMD
NCT02348359Phase 2Terminated
- Sponsor
- Tyrogenex
- Start
- Mar 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vorolanib in exudative macular degeneration (4 arms), sponsored by Tyrogenex. Primary endpoint: Change in Visual Acuity Score at 52 weeks. Started Mar 2015; status: terminated.
02
Drugs
vorolanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02348359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348359.